Manipulating T regulatory cells in cancer immunotherapy

Jens Rüter, Brian G. Barnett, Ilona Kryczek, Michael J. Brumlik, Benjamin J. Daniel, George Coukos, Weiping Zou, Tyler J Curiel

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Malignant tumors express associated antigens that should make them objects of immune attack. Nonetheless, spontaneous immune clearance of established cancer is rare. Recent evidence demonstrates that cancers use active mechanisms to block host antitumor immunity. Significant evidence implicates CD4+CD25+ regulatory T cells (Tregs) as an important mechanism of active immune evasion in cancer. Animal models for cancer demonstrate that Treg depletion improves antitumor immunity and the success of immunotherapy. Thus, blocking Treg function could improve human cancer immunotherapy, where successes have been modest to date. The authors propose four means to block Treg activity: direct elimination; or interference with Treg trafficking, differentiation or function. The fusion toxin denileukin diftitox (Ontak®) eliminates Tregs in some human cancers. The authors discuss their preliminary experience with this agent in human cancer, and discuss progress attempting other strategies to block Treg activity. Reversing tumor-mediated mechanisms hindering host immunity represents a novel approach to tumor immunotherapy.

Original languageEnglish (US)
Pages (from-to)589-597
Number of pages9
JournalExpert Review of Dermatology
Volume1
Issue number4
DOIs
StatePublished - Aug 1 2006
Externally publishedYes

Keywords

  • immune suppression
  • immunopathology
  • immunotherapy
  • Ontak
  • T cell
  • T regulatory cell

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Manipulating T regulatory cells in cancer immunotherapy'. Together they form a unique fingerprint.

  • Cite this

    Rüter, J., Barnett, B. G., Kryczek, I., Brumlik, M. J., Daniel, B. J., Coukos, G., Zou, W., & Curiel, T. J. (2006). Manipulating T regulatory cells in cancer immunotherapy. Expert Review of Dermatology, 1(4), 589-597. https://doi.org/10.1586/17469872.1.4.589